Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1364 - Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes within fibrotic foci of tumor stroma (FF-TILs) (64P)


18 Nov 2017


Poster lunch


Cytotoxic Therapy;  Pathology/Molecular Biology;  Breast Cancer


Shinichiro Kashiwagi


Annals of Oncology (2017) 28 (suppl_10): x16-x24. 10.1093/annonc/mdx655


S. Kashiwagi, Y. Asano, W. Goto, K. Takada, T. Takashima, T. Morisaki, S. Noda, N. Onoda, K. Hirakawa, M. Ohira

Author affiliations

  • Department Of Surgical Oncology, Osaka City University Medical School, 545-8585 - Osaka/JP


Abstract 1364


Monitoring the host immune response to tumors in the cancer microenvironment helps predict treatment response and outcome. Tumor-infiltrating lymphocytes (TILs), which are indicators for monitoring an immune response, are generally mononuclear immunocytes that aggregate with tumors and are thought to have a close relationship with cancer cells. On the other hand, a fibrotic focus (FF) within the stroma of a tumor is a histological formation that plays an important role in the cancer microenvironment with regard to proliferation and development. Here, we focus on TILs that exist within the FF and we have performed pathological evaluations. Among patients undergoing neoadjuvant chemotherapy (NAC) for breast cancer, we evaluated the prediction of treatment effects using FF-TILs.


Of the 320 patients were treated with NAC, 239 subjects who were able to evaluate FF-TILs were targeted. The FF is a converged focus of the tissue component of the stroma of a tumor, and it is surrounded by infiltrating tumor cells. Lymphocytes that infiltrate the FF are FF-TILs.


The disease-free survival (DFS) period after NAC for the high-FF-TIL group was found to be significantly longer than that for the low-FF-TIL group for all cases (p 


It is suggested that FF-TILs are a useful factor for predicting recurrence of breast cancer after NAC.

Clinical trial identification

Legal entity responsible for the study

Shinichiro Kashiwagi




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.